VivoSim Labs, Inc. (VIVS): Revenue
$131.0K
Year ended 2026-03-31
$112.0K
Trailing 12 months to 2026-06-30
-29.3%
3-year compound annual growth
-21.5%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $131.0K | -9.0% | 2026-07-14, From 2025-04-01 |
| 2025-03-31 | $144.0K | +32.1% | 2026-07-14, From 2024-04-01 |
| 2024-03-31 | $109.0K | -70.5% | 2025-06-05, From 2023-04-01 |
| 2023-03-31 | $370.0K | -75.3% | 2024-05-31, From 2022-04-01 |
| 2022-03-31 | $1.50M | n/a | 2023-07-14, From 2021-04-01 |
| 2021-03-31 | $0 | -100.0% | 2022-06-10, From 2020-04-01 |
| 2020-03-31 | $2.20M | -29.0% | 2021-06-15, From 2019-04-01 |
| 2019-03-31 | $3.09M | -32.8% | 2020-05-28, From 2018-04-01 |
| 2018-03-31 | $4.60M | +8.8% | 2019-06-03, From 2017-04-01 |
| 2017-03-31 | $4.23M | +185.2% | 2018-05-31, From 2016-04-01 |
| 2016-03-31 | $1.48M | +159.7% | 2018-05-31, From 2015-04-01 |
| 2015-03-31 | $571.0K | +50.7% | 2017-06-07, From 2014-04-01 |
| 2014-03-31 | $379.0K | n/a | 2016-06-09, From 2013-04-01 |
| No annual figure between 2012-12-31 and 2014-03-31. | |||
| 2012-12-31 | $1.20M | +23.5% | 2015-06-09, From 2012-01-01 |
| 2011-12-31 | $969.0K | n/a | 2014-06-10, From 2011-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $131.0K | -9.0% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $157.2K | +468.6% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $190.0K | -19.1% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $88.0K | -48.2% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $50.0K | +257.1% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $42.0K | -76.8% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $593.0K | -13.2% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $22.0K | n/a |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $800.0K | -77.1% |
Compare VIVS, ZIVO, ATYR, AIM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗